Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
FT819 in Moderate to Severe Active Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT06308978
- Locations
- 🇺🇸
University of Minnesota Medical School, Minneapolis, Minnesota, United States
🇺🇸University of Nebraska Medical Center, Omaha, Nebraska, United States
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 351
- Registration Number
- NCT06241456
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
- Conditions
- Interventions
- Locations
- 🇺🇸
Local Institution - 0068, Morgantown, West Virginia, United States
🇺🇸Local Institution - 0121, New York, New York, United States
🇫🇷Local Institution - 0036, Montpellier, Languedoc-Roussillon, France
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
- Conditions
- Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory Mantle Cell LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaB-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- Biological: Autologous BAFFR-targeting CAR T CellsDrug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 27
- Registration Number
- NCT06191887
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1080
- Registration Number
- NCT06191744
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States
🇺🇸Christiana Care Health Service /ID# 261207, Newark, Delaware, United States
🇺🇸Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Bridge TherapyProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Multigated Acquisition ScanBiological: T-cell Receptor-engineered T-cellsProcedure: X-Ray Imaging
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06094842
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 478
- Registration Number
- NCT06091254
- Locations
- 🇪🇸
Hospital Clinico Universitario Valencia, Valencia, Spain
🇪🇸Hospital Universitary and Politecnic La Fe, Valencia, Spain
🇨🇭Kantonsspital Baden, Baden, Aargau, Switzerland
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇦🇺
Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia
🇦🇺Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia
🇦🇺Epworth Hospital, Richmond, Victoria, Australia
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
- Conditions
- Interventions
- Drug: BendamustineProcedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyDrug: CyclophosphamideProcedure: EchocardiographyDrug: FludarabineProcedure: LeukapheresisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanProcedure: Positron Emission TomographyBiological: T-cell Receptor-engineered T-cells
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06043713
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05979948
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.